We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

51 hedge funds and large institutions have $10.3M invested in Aevi Genomic Medicine Inc in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 12

30% less funds holding

Funds holding: 73 → 51 (-22)

46% less capital invested

Capital invested by funds: $19.2M → $10.3M (-$8.93M)

66% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 32

84% less call options, than puts

Call options by funds: $13K | Put options by funds: $82K

Holders
51
Holders Change
-22
Holders Change %
-30.14%
% of All Funds
1.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
15
Reduced
12
Closed
32
Calls
$13K
Puts
$82K
Net Calls
-$69K
Net Calls Change
-$2.26M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.45M
2
Goldman Sachs
Goldman Sachs
New York
+$262K
3
ECM
Element Capital Management
New York
+$180K
4
LP
LMR Partners
United Kingdom
+$162K
5
PP
Paloma Partners
Connecticut
+$142K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.99M
2
BlackRock
BlackRock
New York
-$1.85M
3
SFM
Sphera Funds Management
Israel
-$753K
4
State Street
State Street
Massachusetts
-$494K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$365K
Name Holding Trade Value Shares
Change 		Change in
Stake
SQA
26
Simon Quick Advisors
New Jersey
$32K – – –
Squarepoint
27
Squarepoint
New York
$32K +$35.1K +24,289 New
Wolverine Trading
28
Wolverine Trading
Illinois
$31K +$33.3K +23,036 New
OIA
29
OneDigital Investment Advisors
Kansas
$28K +$30.1K +20,839 New
State Street
30
State Street
Massachusetts
$27K -$494K -341,975 -94%
WPC
31
White Pine Capital
Minnesota
$27K – – –
JP Morgan Chase
32
JP Morgan Chase
New York
$22K +$737 +510 +3%
VanEck Associates
33
VanEck Associates
New York
$22K +$2.67K +1,846 +13%
CDH
34
Charles D. Hyman
$20K – – –
TRCT
35
Tower Research Capital (TRC)
New York
$14K +$15K +10,365 New
Two Sigma Advisers
36
Two Sigma Advisers
New York
$13K -$3.04K -2,100 -17%
Bank of America
37
Bank of America
North Carolina
$13K +$3.78K +2,615 +38%
PVH
38
Psagot Value Holdings
Israel
$5K +$194 +134 +4%
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
$3K -$1.68K -1,165 -37%
LA
40
Legacy Advisors
Pennsylvania
$3K – – –
UBS Group
41
UBS Group
Switzerland
$2K -$9.27K -6,411 -76%
MAM
42
Meeder Asset Management
Ohio
$2K +$1.24K +859 +148%
AG
43
Advisor Group
Arizona
$1K – – –
IA
44
IFP Advisors
Florida
$1K – – –
KTC
45
Kistler-Tiffany Companies
Pennsylvania
$1K – – –
LTFS
46
Ladenburg Thalmann Financial Services
Florida
$1K – – –
TWA
47
TCI Wealth Advisors
Arizona
$1K – – –
IWM
48
IHT Wealth Management
Illinois
$6 – – –
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$3 -$46 -32 -94%
OM
50
Opaleye Management
Massachusetts
– -$1.99M -1,070,000 Closed
1
2
3 4

GNMX Hedge Fund Activity: Q2 2017 in Review

51 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2017, worth a combined $10.3M — down 46% from $19.2M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of GNMX and 11 opened new positions — a net loss of 21 holders — while 12 trimmed existing stakes and 15 added.

The largest buyer was Adage Capital Partners, adding an estimated $1.45M. The largest seller was Opaleye Management, exiting entirely with an estimated $1.99M sold.

  • 51 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2017, down from 73 in Q1 2017.
  • Funds reported $10.3M of Aevi Genomic Medicine Inc stock for Q2 2017, down 46% quarter-over-quarter.
  • 11 funds opened new Aevi Genomic Medicine Inc positions in Q2 2017 and 32 closed out, a net change of -21 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q2 2017 was Adage Capital Partners, an estimated $1.45M added.
  • The largest Aevi Genomic Medicine Inc seller in Q2 2017 was Opaleye Management, an estimated $1.99M sold.

Based on aggregated 13F filings for Q2 2017.